Eisai retreats from Biogen deal on Aduhelm

15 March 2022

Japanese drugmaker Eisai (TYO: 4523) has backed out of its 50:50 profit sharing deal with US biotech company Biogen (Nasdaq: BIIB) on the Alzheimer’s drug Aduhelm (aducanumab).

Effective as of January 1, 2023, Eisai will receive tiered royalties based on net sales of Aduhelm rather than sharing global profits and losses. The royalty rate starts at 2% and reaches 8% when, or if, annual sales exceed $1 billion.

"The goal of maximizing the value of both Aduhelm and lecanemab"As from now, Biogen’s existing final decision-making rights on Aduhelm have converted to sole decision making and commercialization rights worldwide.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK